Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma.
Uemura M, Nakaigawa N, Sassa N, Tatsugami K, Harada K, Yamasaki T, Matsubara N, Yoshimoto T, Nakagawa Y, Fukuyama T, Oya M, Shinohara N, Uemura H, Tsuzuki T. Uemura M, et al. Among authors: yoshimoto t. Int J Clin Oncol. 2021 Nov;26(11):2085-2086. doi: 10.1007/s10147-021-02008-5. Int J Clin Oncol. 2021. PMID: 34449010 Free PMC article. No abstract available.
Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study.
Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Kimura G, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H. Tsuzuki T, et al. Among authors: yoshimoto t. Pathology. 2023 Feb;55(1):31-39. doi: 10.1016/j.pathol.2022.07.013. Epub 2022 Sep 20. Pathology. 2023. PMID: 36241555 Free article.
Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.
Tamada S, Nozawa M, Ohba K, Mizuno R, Takamoto A, Ohe C, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Kimura G, Tomita Y, Nonomura N, Eto M. Tamada S, et al. Among authors: yoshimoto t. Int J Clin Oncol. 2023 Feb;28(2):289-298. doi: 10.1007/s10147-022-02256-z. Epub 2022 Dec 19. Int J Clin Oncol. 2023. PMID: 36534263 Free PMC article.
Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm.
Narita Y, Yoshimoto T, Namai T, Asakawa T, Kawakami S, Gower-Page C, Reyes-Rivera I, Patel A, Nakamura Y. Narita Y, et al. Among authors: yoshimoto t. JCO Clin Cancer Inform. 2022 May;6:e2200022. doi: 10.1200/CCI.22.00022. JCO Clin Cancer Inform. 2022. PMID: 35649212 Free PMC article. Clinical Trial.
2,103 results